The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association
study of late-onset Alzheimer disease using a three-stage design consisting of a discovery …

ALZHEIMER'S disease is characterized by the extracellular deposition in the brain and its
blood vessels of insoluble aggregates of the amyloid β-peptide (Aβ), a fragment, of about 40 …

Epidemiological studies have documented a reduced prevalence of Alzheimer's disease
among users of nonsteroidal anti-inflammatory drugs (NSAIDs) 1 , 2 , 3 , 4 , 5 . It has been …

Intracellular trafficking and proteolytic processing of amyloid precursor protein (APP) have
been the focus of numerous investigations over the past two decades. APP is the precursor to …

Our understanding of Alzheimer’s disease pathogenesis is currently limited by difficulties in
obtaining live neurons from patients and the inability to model the sporadic form of the …

Amyloid beta-protein (A beta), the 40-43-amino acid polypeptide that is the principal constituent
of senile plaques found in Alzheimer's disease, is constitutively produced and released …

The β-amyloid protein (β/A4), derived from a larger amyloid precursor protein (APP), is the
principal component of senile plaques in Alzheimer's disease. APP is an integral membrane …

PROGRESSIVE cerebral deposition of the amyloid β-peptide is an early and invariant
feature of Alzheimer's disease. The β-peptide is released by proteolytic cleavages from the β-…

Profound neuronal dysfunction in the entorhinal cortex contributes to early loss of short-term
memory in Alzheimer's disease 1 , 2 , 3 . Here we show broad neuroprotective effects of …

In the brains of aged humans and cases of Alzheimer disease, deposits of amyloid in senile
plaques are located in proximity to nerve processes. The principal component of this …